Skip to main content
FRMSP logo

FRMSP — Investor Relations & Filings

Ticker · 6838 ISIN · TW0006838006 TW Professional, scientific and technical activities
Filings indexed 32 across all filing types
Latest filing 2026-04-07 Director's Dealing
Country TW Taiwan
Listing TW 6838

About FRMSP

www.formosapharma.com

Formosa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies within the fields of ophthalmology, oncology, and anti-infectives. The company utilizes its proprietary Activus Pure Nano-technology (APNT®) platform to enhance the formulation of poorly soluble drugs, improving bioavailability and efficacy. Its lead product, APP13007, is a clobetasol propionate ophthalmic suspension developed for the treatment of post-operative inflammation and pain following ocular surgery, which has received regulatory approval in the United States. Formosa Pharmaceuticals focuses on the 505(b)(2) regulatory pathway and the development of antibody-drug conjugates (ADCs). The company actively pursues global licensing and co-development partnerships to advance its pipeline of high-value therapeutic assets.

Recent filings

Filing Released Lang Actions
115年03月董事會成員及持股
Director's Dealing Classification · 90% confidence The document contains a detailed table of insider holdings and pledge status for company directors and senior executives. It reports personal shareholdings of board members, independent directors, and management. This corresponds to insider share transaction disclosures. Therefore, it falls under Director’s Dealing (insider transactions) rather than a general report or meeting announcement.
2026-04-07 Chinese
114年第4季海外子公司投資
Interim / Quarterly Report Classification · 95% confidence The document is a financial disclosure from the Taiwan Stock Exchange's Market Observation Post System (MOPS) regarding '114年4季' (Q4 2025) investment details in overseas subsidiaries. It provides specific financial data (investment amounts, equity percentages, and profit/loss) for a subsidiary. Since it contains substantive financial data for a specific period and is not merely an announcement of a report, it qualifies as an Interim/Quarterly Report (IR) under the provided definitions. Q4 2025
2026-03-31 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.